Correction: Mapping Immunometabolic Reprogramming in IDD
Overview
Revise to remove unsupported claims about the impact of corrections on conclusions.
Background
Intervertebral disc degeneration (IDD) is increasingly recognized as an immune-disturbed and metabolically compromised condition. Understanding the role of mesenchymal stromal cells (MSCs) and their extracellular vesicles (EVs) in this context is crucial for advancing therapeutic strategies. Accurate reporting of findings is essential for the scientific community to build upon existing research.
Data Highlights
No numerical or trial data is presented in the correction article.
Key Findings
Correction of an omitted citation to Supplementary Figure 1 in Section 3.1.
Correction of an incorrect citation to Figure 2C in Section 3.2.
The original sentence regarding quality control was amended to include the correct citation.
The sentence about obtaining 16 EV-score–linked genes was corrected to remove the erroneous figure reference.
The authors confirmed that these corrections do not affect the study's conclusions.
Clinical Implications
Accurate reporting in scientific literature is vital for clinicians and researchers to rely on findings for future studies and clinical applications. The corrections made in this article ensure the integrity of the research on IDD and its immunometabolic aspects.
Conclusion
The corrections made in this article clarify previous inaccuracies without impacting the overall findings. Continued attention to detail in scientific reporting is essential for advancing knowledge in intervertebral disc degeneration.
